FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasnington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIA	L OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LAWLOR AUGUSTINE</u>					2. Issuer Name and Ticker or Trading Symbol CATALYST BIOSCIENCES, INC. [CBIO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) 47 THO:	(First) (Middle) HORNDIKE STREET TE B1-1		08	/20/20)15				n/Day/Year)		below)	Officer (give title below)			er (spe w)				
(Street)	IDGE M	IA	02141		- 4. I	f Amer	ndment, [Oate (of Origina	al File	d (Month/Da		Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(S	state)	(Zip)																
		Tak	le I - N	on-Deri	vativ	e Sec	curities	Ac	quired	l, Di	sposed o	f, or Bei	neficia	lly Owned	l				
Da		2. Transa Date (Month/Da	ay/Year) if a		2A. Deemed Execution Date, f any Month/Day/Year)				Disposed O	ties Acquired (A) or I Of (D) (Instr. 3, 4 and		5. Amount of Securities Beneficially Owned Followir Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Indirect			
								Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			(111341. 4)			
Common Stock 08/2			08/20/	/2015	2015		J ⁽¹⁾		1,041,024	4 A	(1)	1,041,	.024		I Ver		thCare cures , L.P. ⁽²⁾		
		-	Table II								osed of, convertil			/ Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year) (Month/		n Date,		ansaction of ode (Instr. Derivative		ve es d ed nstr.	6. Date Exercisable Expiration Date (Month/Day/Year)		te	7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares						
Warrant (Right to Buy)	\$33.27	08/20/2015			J ⁽³⁾		2,254		(3)		04/09/2019	Common Stock	2,254	(3)	2,2	254	· I		By HealthCare Ventures VIII, L.P. (2)
Warrant (Right to Buy)	\$3.33	08/20/2015			J ⁽⁴⁾		11,383		(4)		05/29/2020	Common Stock	11,383	(4)	11,	383	I	I V	By HealthCare Ventures VIII, L.P. (2)
Warrant (Right to Buy)	\$3.33	08/20/2015			J ⁽⁵⁾		14,056		(5)		06/29/2020	Common Stock	14,056	(5)	14,	056	I	I V	By HealthCare Ventures VIII, L.P. (2)

Explanation of Responses:

- 1. Represents shares of the Issuer issued pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 5, 2015 as amended on May 6 and May 13, 2015, by and among the Issuer, Talos Merger Sub, Inc. and a Delaware corporation then known as Catalyst Biosciences, Inc. ("Old Catalyst"). Pursuant to the terms of the Merger Agreement, each share of common stock of Old Catalyst was converted into 0.0382 shares of the Issuer's common stock.
- 2. HealthCare Ventures VIII, L.P. ("HCVVIII") is the registered owner of the securities. The Reporting Person is a managing director of HealthCare Partners VIII, L.P. ("HCPVIII LLC"), the General Partner of HealthCare Partners VIII, L.P. ("HCPVIII"). HCPVIII is the General Partner of HCVVIII. The Reporting Person shares voting and investment power over the shares held by HCVVIII with each of Christopher Mirabelli, James Cavanaugh, John Littlechild and Harold Werner as managing directors of HCPVIII LLC. The Reporting Person disclaims beneficial ownership of those securities in which he does not have a pecuniary interest and this report shall not be deemed an admission that he is the beneficial owner of these securities for purposes of Section 16, except to the extent of his pecuniary interest therein.
- 3. On April 9, 2014, HCVVIII acquired a warrant to purchase 59,027 shares of the Series E Preferred Stock of Old Catalyst at an exercise price of \$1.2706 per share. Each share of Series E Preferred Stock of Old Catalyst was convertible into 1 share of common stock of Old Catalyst. Pursuant to the Merger Agreement, this warrant was converted into a warrant to purchase 2,254 shares of the Catalyst's common stock at a per share exercise price of \$33.27. The warrant is fully vested and exercisable.
- 4. On May 29, 2015, HCVVIII acquired a warrant to purchase 29,800 shares of the Series F Preferred Stock of Old Catalyst at an exercise price of \$1.2706 per share. Each share of Series F Preferred Stock of Old Catalyst was convertible into 10 shares of common stock of Old Catalyst. Pursuant to the Merger Agreement, this warrant was converted into a warrant to purchase 11,383 shares of the Catalyst's common stock at a per share exercise price of \$3.33. The warrant is fully vested and exercisable.
- 5. On June 29, 2015, HCVVIII acquired a warrant to purchase 36,796 shares of the Series F Preferred Stock of Old Catalyst at an exercise price of \$1.2706 per share. Each share of Series F Preferred Stock of Old Catalyst was convertible into 10 shares of common stock of Old Catalyst. Pursuant to the Merger Agreement, this warrant was converted into a warrant to purchase 14,056 shares of the Catalyst's common stock at a per share exercise price of \$3.33. The warrant is fully vested and exercisable.

Remarks:

/s/ Nassim Usman Attorney-in-Fact for Augustine Lawlor

08/20/2015

** Signature of Reporting Person

Date

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.